Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05832567 · ClinicalTrials.gov registry record · NA
Mechanisms of Open and Hidden Placebo in Stroke Recovery
A NA study of Stroke and Hemiparesis, sponsored by Spaulding Rehabilitation Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT05832567: Recruiting NA study of Stroke and Hemiparesis, sponsored by Spaulding Rehabilitation Hospital.
NCT05832567 is a NA study of Stroke and Hemiparesis that is actively recruiting participants, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 56 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05832567, a NA study of Stroke and Hemiparesis, is actively recruiting participants, sponsored by Spaulding Rehabilitation Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial aims to investigate whether placebo in isolation (open and hidden) has a specific neural signature in stroke subjects thus providing a novel mechanism to explain placebo effects that can be used to ultimately enhance stroke rehabilitation therapies.
Primary Outcome
The FAA score will be calculated by subtracting the natural log-transformed alpha power in the left frontal region (F3, F7, Fp1) from the natural log-transformed power in the right frontal region (F4, F8, Fp2).
Conditions Studied
Interventions
- DEVICE Active rTMS
- DEVICE Sham rTMS
- DIETARY_SUPPLEMENT Open Placebo
Study Locations (1)
Massachusetts
- Spaulding Hospital Cambridge - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05832567 shows while recruiting
NCT05832567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which Active rTMS is the first listed.
NCT05832567 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05832567 about?
NCT05832567 is a clinical study titled "Mechanisms of Open and Hidden Placebo in Stroke Recovery". This trial aims to investigate whether placebo in isolation (open and hidden) has a specific neural signature in stroke subjects thus providing a novel mechanism to explain placebo effects that can be used to ultimately enhance stroke rehabilitation therapies.
What is the current status of trial NCT05832567?
This trial is currently recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2023-09-11. Estimated completion is 2026-06-30.
What conditions does trial NCT05832567 study?
This clinical trial studies the following conditions: Stroke, Hemiparesis.
What interventions are being tested in trial NCT05832567?
The interventions under investigation include: Active rTMS (DEVICE), Sham rTMS (DEVICE), Open Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05832567?
This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05832567 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05832567's enrollment target sits among peer trials
56 220th of 454 higher than 231 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI